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Background: Osteosarcoma is the most common of all the bone malignancies and accounts for 30-80 % of the
primary skeletal sarcomas. The overall survival rate of patients with osteosarcoma is < 20 % suggesting poor prognosis.
Methods: The present study demonstrates the effect of retinoic acid chlorochalcone (RACC) incorporated glycol
chitosan (GC) nanoparticle transfection in osteosarcoma cells. MG-63 and Saos-2 osteosarcoma cells were transfected
with various concentrations of RACC-incorporated GC nanoparticle for 24 h. The effect on cell proliferation, Ezh2
expression, apoptosis, cell cycle arrest, cell migration and invasiveness, Akt phosphorylation and local tumour growth
and metastases were studied.
Results: MG-63 and Saos-2 osteosarcoma cells on RACC-incorporated GC nanoparticle transfection for 24 h showed a
concentration-dependent inhibition of cell proliferation. Of the various concentrations of RACC tested, the effective
concentration started from 5 μM with an IC50 of 20 μM. Wound healing assay also showed that RACC-incorporated GC
nanoparticles inhibited migration of tumor cells more effectively compared to the parent RA. RACC transfection
resulted in inhibition of cell proliferation, Ezh2 expression inhibition, apoptosis through mitochondrial pathway by
decrease in membrane potential and release of cytochrome c and cell cycle arrest in the G0/G1 phase. The invasiveness
of cells treated with 5 and 20 μM RACC was decreased by 49 and 76 % respectively, compared to the control.
RACC-treated mice showed significantly lower number of metastases compared to that in the control mice.
Conclusions: Thus, RACC-incorporated glycol chitosan nanoparticle strategy can be promising for the treatment of
osteosarcoma.
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Osteosarcoma is the most common of all the bone ma-
lignancies and accounts for 30-80 % of the primary skel-
etal sarcomas [1, 2]. It frequently attacks the children,
teenagers, and young adults between 10–30 years of age
[3]. Compared to females osteosarcoma is more predom-
inantly observed in males. The long cylindrical bones
like femur, tibia, and humerus including the knee joint
are the main target in osteosarcomas [4]. However, the
shoulder blade, pelvic, and skull bones are also sometimes
affected [5]. Osteosarcoma is a well-defined clinical entity* Correspondence: qinyanguo0987@gmail.com
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features, a relatively consistent spectrum of clinical pre-
sentations, and established standard treatments. These
features have been the subject of many prior book chap-
ters and reviews [6–11]. However, all of the present
treatments are less efficient. Therefore, the discovery of
molecules with roles in the osteosarcoma inhibition is
highly desired to improve the clinical treatment.
Polycomb group of genes (PcG) which play a crucial
role epigenetically in regulating gene transcription pro-
grams possess a catalytic subunit, Enhancer of Zeste
homolog 2 (Ezh2) [12]. It has been demonstrated that
Ezh2 controls expansion and differentiation of tumor
initiating cells and the development and progression of
cancer [13–15]. In Myelodysplastic syndromes Ezh2le distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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cell differentiation to maintain stemness of tumor
cells [18, 19].
Retinoic acids (RAs) have been used in the prevention
and treatment of dermatological diseases [20, 21]. Re-
cently retinoic acid and other retinoids have been re-
ported to possess promising anti-cancer activity [22]. It
was demonstrated that retinoic acids affect in vitro pro-
liferation, differentiation, and apoptosis of colon [23],
prostate [24], lung [25], and leukemia [26] cancers.
Moreover, retinoc acids also influence the morphological
differentiation, proliferation, and gene expression of
neuroblastoma [27] and astrocytoma cells [28]. Recur-
rent malignant cerebral gliomas have been treated with
ATRA [29, 30] and 13-cis RA [31]. Despite of its in vitro
biological promise, its poor bioavailability under in vivo
restricts its clinical applications [32]. One of the tech-
niques to overcome this drawback is the development of
polymeric micelles [33], like glycol chitosan micelle. Tak-
ing cue from the above literature we devised an experi-
ment to study the effect of RACC (Fig. 1) having more
bioavailability compared to the parent compound on hu-
man glioma.
Results
RACC-incorporated GC nanoparticles cause proliferation
inhibition in human osteosarcoma cells
The results from MTT assay revealed a dose-dependent
inhibition of the MG-63 and Saos-2 cell proliferation on
RACC treatment after 24 h. Among the range of con-
centrations from 1 to 20 μM tested, the inhibition was
significant at 5 μM with a reduction in O.D. values of
16 ± 0.6 and 13 ± 0.8 % for MG-63 and Saos-2 cell lines
respectively. The reduction in O.D. values at 10, 15 andFig. 1 Structure of retinoic acid chlorochalcone (RACC) and glycol chitosan20 μM was 23 ± 2, 63 ± 3.5, 90 ± 10 % for MG-63 and 36
± 3.2, 64 ± 3.43 and 89 ± 10.34 for Saos-2 cells respect-
ively. The IC50 values of RACC were 18.2 ± 2.8 μM for
both the tested cell lines.
The daily MTT assay using 20 μM RACC for 4 days
showed that growth inhibition for both the cell lines was
maximum at day 4 (Fig. 2a,c). The trypan blue exclusion
assay showed drop in cell number in a time-dependent
manner (Fig. 2b,d).
RACC-incorporated GC nanoparticle transfection inhibits
Ezh2 expression in human osteosarcoma cells
We used Western blot and RT-PCR analysis to examine
the changes in Ezh2 and protein expression levels in
MG-63 and Saos-2 cells on RACC-incorporated GC
nanoparticle treatment. The results showed a significant
decrease in Ezh2 expression level after 24 h of RACC-
incorporated GC nanoparticles (20 μM) transfection
compared to control. The Ezh2 inhibition by RACC
lasted for at least 72 h after the RACC-incorporated GC
nanoparticle transfection (Fig. 3). These results suggest
that after the transfection of the RACC at 20 μM for
24 h, the Ezh2 and protein expression levels are effect-
ively inhibited.
RACC-incorporated GC nanoparticles induce apoptosis in
MG-63 and Saos-2 human osteosarcoma cells
We used flow-cytometric and ssDNA detection assay to
examine apoptotic cell death in osteosarcoma cells. In
MG-63 cells treatment with 5 and 20 μM RACC in-
duced apoptosis in 5.89 ± 3.9 and 60.54 ± 5.4 % cells re-
spectively compared to 2.05 ± 1.01 % cells in control
(Fig. 4). Similar results were observed in Saos-2 cells,
where in exposure to 5 and 20 μM RACC induced(GC)
Fig. 2 RACC-incorporated GC nanoparticles induced time-dependent inhibition of MG-63 and Saos-2 cell proliferation. a and c, MTT tests on
MG-63 and Saos-2 osteosarcoma cell line; b and d, trypan blue tests on MG-63 and Saos-2 osteosarcoma cell line. Cells were cultured in medium
containing empty GC vesicles (□) or RACC-incorporated GC nanoparticles (●) with 20 μM RACC, added at a day “0,” for the time indicated. Results
correspond to three different experiments and values are expressed as mean
Fig. 3 Expression of Ezh2 and protein in MG-63 and Saos-2 cells after RACC transfection. a and c After the MG-63 and Saos-2 cells were
transfected with 20 μM RACC, the expression level of the Ezh2 and proteins was significantly reduced. b The efficacy of RACC to inhibit the Ezh2
expression was further analysed by western blotting analysis
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Fig. 4 RACC-induced apoptosis in MG-63 cells. Cultures were grown either in medium containing empty GC vesicles (control) or in a medium
containing 5 μM or 20 μM RACC. The arrows indicate apoptotic cells; magnified image of cells was shown in corner
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ively compared to 1.79 ± 0.23 % in control cells (data not
shown).
RACC treatment induces apoptosis in the MG-63 and
Saos-2 human osteosarcoma cells through the
mitochondrial pathway
We used JC-1 staining to detect the changes in mito-
chondrial membrane potential in MG-63 and Saos-2 cell
lines. The results clearly showed that increase in concen-
tration of RACC in RACC-incorporated GC nanoparti-
cle from 10 μM to 25 μM significantly reduced the
mitochondrial membrane potential in MG-63 cells
(Fig. 5a). Western blot analysis revealed translocation of
Bax and Bcl-2 proteins from mitochondria to cell cytosol
(Fig. 5b). Similar results were obtained in Saos-2 human
osteosarcoma cell lines.
RACC-incorporated GC nanoparticle transfection causes a
cell cycle arrest in the G0/G1 phase in MG-63 and Saos-2
human osteosarcoma cells
The results from flow cytometry showed a significant in-
crease in G0/G1 cell population in both MG-63 and
Saos-2 cells with subsequent decrease in S and G2/MFig. 5 RACC induces apoptosis in MG-63 cells through the mitochondrial p
analysed by JC-1 staining and subsequent flow cytometry. b The expressio
mitochondria were analysed by western blottingphase on treatment with RACC (5 μM) (Fig. 6). The in-
crease in concentration of RACC from 5 μM to 20 μM
led to further increase in the percentage of cells in G0/
G1 phase and subsequent decrease in cell percentage
from S and G2/M phase (Fig. 6). These results confirm
that RACC transfection arrests cell cycle in G0/G1
phase in human osteosarcoma cell lines.
RACC-incorporated GC nanoparticle transfection inhibits
cell migration and invasiveness
Treatment with RACC (20 μM) for 24 h significantly de-
creased the migratory activity of MG-63 and Saos-2 cells
by 52 and 58 % respectively compared to control cells
(Fig. 7a). The migratory activity of the cells treated with
5 μM RACC was decreased by 10 and 40 % respectively
in MG-63 and Saos-2 cells. In invasion assay, the cap-
acity of the RACC-treated MG-63 cells to pass though
the Matrigel-coated filters was significantly lower com-
pared to control cells (Fig. 7b). The invasiveness of cells
treated with 5 and 20 μM RACC was decreased by 49 %
and 76 % (P < 0.001), respectively, compared to the con-
trol. Knockdown of Has1 and/or Has3 with siRNA re-
vealed that the single knockdown of Has1 or Has3 did
not compensate for the effects of RACC on cell motilityathway. a Changes in the mitochondrial membrane potential were
n levels of Bax, Bcl-2, and cytochrome c in the cytoplasm and
Fig. 6 Effect of RACC transfection on cell cycle arrest in MG-63 and Saos-2 cells. The cell cycle distribution of MG-63 and Saos-2 cells that had
been treated with empty GC vesicles. The cell cycle distribution of MG-63 and Saos-2 cells that had been treated with 5 and 20 μM RACC
incorporated GC nanoparticles
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and Has3 did (Fig. 7c). Thus suggesting the involvement
of HA-dependent route in the inhibitory effects of
RACC on cell motility and invasiveness.
RACC-incorporated GC nanoparticle transfection inhibits
Akt phosphorylation
We also examined the effect of RACC treatment on Akt
phosphorylation in MG-63 and Saos-2 cells using west-
ern blot analysis. The results revealed a significant de-
crease in Akt phosphorylation after 5 and 10 h of RACC
treatment than that in the control cells. However, no dif-
ference was observed at 1 or 2 h (Fig. 7d).
RACC-incorporated GC nanoparticle transfection exhibits
inhibitory effects on local tumour growth and metastases
Administration of 20 μM RACC exhibited an inhibitory
effect on MG-63 tumour growth, based on the reduction
in tumour wet weight (67 % reduction, Fig. 8a). We used
HABP staining to analyse the HA retention in the local
tumour inhibited by RACC treatment. The resultsrevealed a significantly lower HA retention in RACC-
treated local tumours compared to that in the control
tumours (Fig. 8c-e). RACC treatment resulted in a signifi-
cant (84 %) reduction in the number of metastatic lesions
which was visually analysed (Fig. 8b). RACC-treated mice
showed significantly lower number of metastases com-
pared to that in the control mice.
Discussion
In the present study, RACC-incorporated GC nanoparti-
cles formed by electrostatic interaction between –COOH
group of RACC and –NH2 group of glycol chitosan were
prepared. The presence of reactive –NH2 group makes
chitosan a suitable substrate for drug conjugation and ion
complex formation with anionic drugs [14, 34–36]. Thü-
nemann and Beyermann initially developed the concept of
nanoparticle formation acid and positively charged macro-
molecules [29, 30]. Since then nanoparticle targeted treat-
ment of cancer has been studied extensively [31–33].
Taking into consideration poor bioavailability of RACC,
we transfected RACC-incorporated GC nanoparticles into
Fig. 7 Effect of RACC on cell motility, invasiveness, and Akt-phosphorylation. a Cell motility of MG-63 and Saos-2 cells. b Cell invasiveness of
MG-63 cells. The number of cells on the lower surface of the membrane was counted in 20 randomly selected high-power fields. The data are
presented as the average ± s.d. compared with DMSO). c Cell motility and invasiveness of MG-63 cells after knockdown of Has1 and/or Has3. The
data are presented as the average ± s.d. compared with DMSO). d Western blotting for Akt phosphorylation
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proliferation and cell cycle. There was significant inhib-
ition in cell proliferation on treatment with RACC-
incorporated GC nanoparticles at a concentration of
20 μM of RACC within 24 h. The proliferation inhibition
continued for 72 h and the effect was seen to be max-
imum on day 4. Further investigation revealed that RACC
transfection in MG-63 and Saos-2 human osteosarcoma
cells caused inhibition of Ezh2 expression. The inhibition
was seen after 24 h of RACC transfection at 20 μM (IC50
value) concentration and lasted for 72 h. The results from
apoptosis and necrosis assay showed increase in the per-
centage of apoptosis on increasing the concentration of
RACC. Our results from flow-cytometry demonstrate that
osteosarcoma cells undergo apoptosis through mitochon-
drial pathway. The Bax and Bcl-2 proteins were seen to
translocate from mitochondria into cytoplasm where they
led to release of cytochrome c. Cytochrome c then acti-
vates caspase 9 and caspase 3, which play key roles in the
apoptosis pathway [37]. The increase in concentration of
RACC in RACC-incorporated GC nanoparticle from
5 μM to 20 μM significantly reduced the mitochondrial
membrane potential in MG-63 cells. Therefore, theseresults suggest that the RACC inhibition of Ezh2 expres-
sion induces apoptosis through the mitochondrial path-
way in human osteosarcoma cells. Our results from flow
cytometry also suggest that RACC induces cell cycle arrest
in G0/G1 phase. Treatment of MG-63 and Saos-2 cells
with 10 μM concentration of RACC, led to an increase in
the percentage of cells in G0/G1 phase with the subse-
quent decrease in S and G2/M phase. The increase in con-
centration of RACC from 5 μM to 20 μM significantly
increased the percentage of cells in G0/G1 phase.
The results from our study revealed that RACC
exerted a multistep inhibitory effect on the tumourigeni-
city of osteosarcoma cells through inhibition of HA syn-
thesis. HA being the major component of ECM, the
reduction of Has subsequently causes the suppression of
ECM production, particularly that of the cell-associated
matrix. It is reported that cell-associated matrix is linked
to tumourigenicity [38–40]. Our results demonstrate
that the inhibition of cell-associated matrix formation
through suppression of HA synthesis by RACC effectively
suppressed the tumourigenicity. Thus, the anti-tumour ac-
tivity of RACC may be partly through the depletion of
cell-associated matrix formation.
Fig. 8 Effect of RACC on implanted tumour mass and osteosarcoma metastasis of MG-63 cells. a The wet weights of the transplanted tumour
were measured. (b) The numbers of osteosarcoma metastases. Representative sections of transplanted tumours with HABP staining (c and e; Control,
d and f; RACC treatment)
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ling pathway is significantly involved in HA-induced cell
motility and invasiveness. We also demonstrated that
RACC-induced downregulation of Akt phosphorylation
in osteosarcoma cells. Considering the delayed inhibition
of Akt phosphorylation (after 6 h) by RACC in this
study, RACC may indirectly affect Akt phosphorylation,
possibly via suppression of HA synthesis, perturbation
of HA-receptor interaction, or alteration of cell signal-
ling pathways including Akt phosphorylation.
The degree of the inhibitory effects of RACC on the
formation of osteosarcoma metastasis in vivo was mark-
edly higher than that on the growth of the implanted
primary tumour. In contrast to the growth of the pri-
mary tumour, multistep processes are associated with
distant metastasis. In this study, RACC suppressed pro-
liferation, motility, and invasion of osteosarcoma cells
in vitro. Inhibition of these steps by RACC led tosubstantial suppression of tumour metastasis. Another
explanation is that RACC affects the microenvironment
of the primary and target organs. The tumour stroma
and surrounding normal cells (immune cells, inflamma-
tory cells, pericytes, vascular endothelial cells, and fibro-
blasts) can be affected by RACC, possibly via suppression
of HA synthesis. Notably, in the current study, HA de-
posits were markedly suppressed not only in the periphery
of the tumour, but also in the surrounding stromal tissues
and perivascular region in vivo. In the clinical context, the
strong suppressive effects of RACC on lung metastasis
might be especially beneficial for patients with osteosar-
coma, considering that the primary cause of death in this
group is metastasis [41].
Conclusions
The present study demonstrates that RACC inhibits
various processes of tumourigenicity in vitro in murine
Qin et al. Lipids in Health and Disease  (2015) 14:70 Page 8 of 10and human osteosarcoma cell lines, and markedly
suppressed osteosarcoma metastasis. Thus RACC-
incorporated GC nanoparticles may be a promising
strategy for the treatment of osteosarcoma.
Materials and methods
Cell culture
Human osteosarcoma cell lines, MG-63 and Saos-2 were
purchased from the Health Science Research Resources
Bank (Osaka, Japan). The cells were maintained in RPMI
1640 medium (RPMI:ECM = 4:1) supplemented with
10 % fetal bovine serum at 37 °C in 5 % CO2 in a hu-
midified atmosphere.
Chemicals and reagents
Glycol chitosan (GC), retinoic acid chlorochalcone
(RACC), dialysis membranes (MWCO = 12,000 g/mol)
and propidium iodide (PI) were purchased from Sigma
Chem. Co. Ltd. (St. Louis, MO, USA). FITC-annexin V
was obtained from Santa Cruz, CA, 95060, USA.
Ethical statement
The present study was approved by the Institutional
Review Board and Ethics Committee of the Nanjing
University, Jiangsu, China.
Preparation of RA-incorporated GC nanoparticles
The RACC-incorporated GC nanoparticles were pre-
pared by adding a solution containing 5 mg RACC in
1 mL of DMF to an aqueous solution containing 40 mg
of GC in 10 mL of deionized water while stirring. The
stirring was continued for 20 min under darkened con-
ditions. A dialysis membrane (MWCO = 12,000 g/mol,
Sigma Chem. Co. Ltd. St. Louis, MO, USA) was used to
prepare dialyzed solution against deionized water by dia-
lysis for 1 day. Out of 20 mL prepared by adding deion-
ized water to the dialyzed solution, 100 μL was diluted
with 9.9 mL of DMSO. UV spectrophotometer (UV-1200,
Shimadzu Co. Ltd., Kyoto, Japan) was used to measure
drug contents at 365 nm and empty GC vehicles were
used as a blank test.
Proliferation inhibition assay (MTT assay)
In each well of a 96-well plate, aliquots containing
2.5 × 105 cells were seeded. The cells were incubated
overnight in a 5 % CO2 incubator at 37 °C and then
RACC-incorporated GC nanoparticle solution was
added to each well. After dilution with RIMI 1640
(10 % FBS), these were used to treat the tumor cells.
RIMI 1640 (10 % FBS) with 0.1 % (v/v) DMSO was
used as control. The incubation for 48 h was followed
by addition of 25 μL of MTT (3 mg/mL in PBS) to each
well and incubation was continued for 4 h more. To
each well was added 100 μL of SDS–HCl solution (SDS10 % w/v, 0.01 M HCl) and incubated again for 12 h.
An Infinite M200 pro reader (Tecan Austria GmbH,
Salzburg, Austria) was used to measure the absorbance
at 570 nm. The viable cells were expressed as percent-
age of control and all the experiments were conducted
in triplicate.
Western blotting
The transfected osteosarcoma cells from were washed
twice in PBS followed by addition of Lysis buffer
(50 mM Tris–HCl pH 7.4, 137 mM NaCl, 10 % glycerol,
100 mM sodium vanadate, 1 mM PMSF, 10 mg/ml apro-
tinin, 10 mg/ml leupeptin, 1 % NP-40, and 5 mM cock-
tail). Bicinchoninic acid assay (BCA) method was used
to determine protein concentration. Equal amounts of
protein were loaded and resolved by electrophoresis on
a 10 % polyacrylamide gel. The semi-dry method was
used to transfer proteins onto a PVDF membrane which
was then blocked with 5 % non-fat dry milk overnight.
After TBST washing, membrane was incubated for 2 h
with primary antibodies and then washed again with
TBST before incubation with secondary antibodies for
2 h. Then X-ray autoradiography was performed and the
gray scale images were analysed.
Flow cytometric analysis
Identification of apoptosis and necrosis in osteosarcoma
cells was performed by propidium iodide and FITC-
annexin V reagents respectively. Treatment of cells with
various concentrations of RACC-incorporated GC nano-
particles for 24 h was followed by washing with PBS.
After suspension in binding buffer (10 mM HEPES
pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2, and
1.8 mM CaCl2) containing FITC annexin V (1 μg/mL)
the pellets were incubated for 20 minutes. Then PI
(10 μg/mL) was added to stain necrotic cells under dark
conditions and incubation was continued for 10 minutes
more. FAC Scan flow cytometer (Becton Dickenson
Biosciences, San Jose, CA, USA) was used to analyse
the cells immediately.
Detection of Single-Strand DNA (ssDNA)
In a 96-multiwell plate, 10000 cells/well were seeded
and incubated with the RACC-incorporated GC nano-
particles. The cells were then fixed with 80 % methanol
for 30 minutes. The plates were dried and incubated
with formaldehyde for 10 min at room temperature
followed by 10 min at 75 °C, and then at 4 °C for 5 min.
With 3 % non-fat dry milk cells were incubated for 1 h
followed by incubation with the antibody mixture (con-
taining a primary monoclonal antibody to ssDNA and
horseradish peroxidase-labeled secondary antibody) for
30 min. The addition of 2-2’-azino-bis[3-ethylbenziazo-
line-6-sulfonic acid] solution permitted the reading of
Qin et al. Lipids in Health and Disease  (2015) 14:70 Page 9 of 10the plates at 405 nm in a standard microtiter reader. As
positive control ssDNA and as negative control necrotic
cells obtained by hyperthermia were used.
Immunocytochemistry for Has
Onto the chamber slides (BD Biosciences, Mountain
View, CA, USA) 2.5 × 106 MG-63 cells were seeded and
allowed to stick to the bottom. The cells were then incu-
bated with various concentrations of RACC for 24 h and
subjected to Has1 and Has3 immunocytochemistry. The
antibodies against Has1 and Has3 were raised in rabbits
by subcutaneous injection of the synthetic peptides.
Motility and matrigel invasion assays
Transwell motility chambers were used to analyse cell
migration and invasion. For this, the 8-mm pore diam-
eter transwell motility chambers (Corning) were coated
with matrigel (BD Biosciences) on undesurfaces. Into the
upper chamber, 2 × 106 cells were plated in serum-free
culture medium and the lower chamber was filled with
medium containing 10 % FBS. The plates were incubated
for 24 hours at 37 °C. After incubation the upper surface
of the compartment was cleaned. The inserts after
methanol fixing were stained with crystal violet solution
(0.5 %) followed by microscopic examination. The 5
areas were randomly selected and the cells were calcu-
lated. Experiments were performed in triplicates.
Effects of RACC in vivo
The dorsal flank of 5-week-old C3H/He male mice were
transfected with MG-63 cells (2.5 × 106) suspended in
200 ml of serum-free DMEM. After 14 days of in vivo
growth small tumours (0.6–1.2 cm in diameter) were ob-
served. The mice were then randomly assigned into two
groups with 10 each. The mice in RACC group received
15 mg RACC with 100 ml of 0.4 % CMC solution intra-
peritoneally daily whereas the mice in control group
were given same amount of 0.4 % CMC solution.
Twenty days after the treatment, the mice were sacri-
ficed, and their tumours were excised and analysed for
tumour wet weight and number of metastatic colonies.
All animal experiments were performed in accordance
with the National Cancer Research Institute (2010)
Guidelines for the welfare and use of animals in cancer
research and under approval of the institutional animal
ethics committee.
HA staining for cells and tissues
The hyaluronic acid binding protein (HABP; Seikagaku,
Tokyo, Japan) was used to examine the accumulation of
hyaluronan in cells and in vivo tissues with or without
RACC. MG-63 cells were distributed onto chamber slides
(BD Biosciences) and allowed to adhere to the bottom.
The cells were then incubated with various concentrationsof RACC with or without exogenous 200 mg ml−1 of HA
for 72 h. After HABP staining, the cells and local tumours
were incubated with a 2.0 mg ml−1 biotinylated HABP
probe for 1 h at room temperature. Streptavidin-peroxidase
reagents (Nichirei, Tokyo, Japan) and diaminobenzidine-
containing substrate solution (Nichirei) were used to ana-
lyse b-HABP binding.
HA quantification
MG-63 cells were incubated with or without 20 μM
RACC for 6, 12, and 24 h. The cells were incubated for
10 min at 37 °C with trypsin-EDTA followed by PBS
wash to remove the cell-surface-associated HA. The
cells were then placed in Protease K solution (0.15 M
Tris–HCl, pH 7.5, 0.15 M NaCl, 10 mM CaCl2, and
5 mM deferoxamine mesylate containing 20 units of
protease K) and incubated for 2 h at 55 °C. For inactiva-
tion of the protease activity samples were heated at
100 °C for 20 min and centrifuged at 12 000 g for
45 min at 4 °C. The supernatants were analysed for HA
concentrations using a sandwich enzyme-linked im-
munosorbent assay.
Statistical analysis
The in vitro quantitative experiments were performed in
triplicates, and analysis of variance followed by Bonferroni-
Dunn post-hoc test was used to assess differences between
means. Student’s t-test was used for statistical comparisons
between the two groups.
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